Nano Med Tech, a newly emerging leader in nano-technological cancer research and treatment, announced that its sales team for America is in place and that stateside medical marketing will commence, soon.
FOR IMMEDIATE RELEASE
With a Commercial Director and eight account managers in place,
Nano Med Tech will now seek to make its therapy available in
medical institutions throughout the United States. The organization has received USFDA approval for its patented medical devices, which utilize advanced nanoparticles for the treatment of malignant tumors.
Phillip Skellar joins the company as US Sales Director and will head the company’s commercialization efforts. Mr. Skellar has over 25 years of experience in the pharmaceutical industry, including extensive experience in the area of oncology. His professional experience includes a leading position held at Eli Lilly.
"I am extremely pleased to welcome Phil Skellar and his team of account managers to Nano Med Tech. The implementation of commercializing the fruits of our research is a major milestone in transitioning Nano Med Tech from a research organization into a commercially operating entity," said William Hung, spokesman for the company.